[A16-14] Osimertinib - Benefit assessment according to §35a Social Code Book V
Last updated 15.09.2016
Commission awarded on 15.03.2016 by the Federal Joint Committee (G-BA).
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A18-45||Osimertinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A17-20||Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V||Commission completed|